PD-L1 – Talk Bio

Actionable Insights Powered by AI

Merck & Co. Announces Keytruda Achieves First Overall Survival Benefit in Resistant Ovarian Cancer

2 weeks ago talkbio0Tagged checkpoint inhibitor, Co., KEYNOTE-B96 trial, Keytruda, Merck, ovarian neoplasm, Overall Survival, PD-L1, pembrolizumab, platinum-resistant, Progression-Free Survival

Merck & Co.; Keytruda; pembrolizumab; ovarian cancer; platinum-resistant; overall survival; checkpoint inhibitor; KEYNOTE-B96 trial; progression-free survival; PD-L1

Moderna Unveils Promising mRNA-4359 Cancer Antigen Therapy Data in Melanoma Ahead of ESMO 2025

2 weeks ago talkbio0Tagged cancer antigen therapy, checkpoint inhibitor-resistant, disease control rate, Frequency of Responses, IDO1, Immunotherapy, melanoma, Moderna, mRNA-4359, PD-L1, pembrolizumab, Phase 1/2 trial

Moderna; mRNA-4359; cancer antigen therapy; melanoma; ESMO 2025; checkpoint inhibitor-resistant; PD-L1; IDO1; objective response rate; disease control rate; immunotherapy; Phase 1/2 trial; pembrolizumab

Recent Trends in Biomarker Testing for NSCLC: Maximizing Real-World Survival

3 weeks ago talkbio0Tagged ALK gene, biomarker testing, Epidermal Growth Factor Receptor, Liquid Biopsy, next-generation sequencing, Non-Small Cell Lung Carcinoma, Overall Survival, PD-L1, Precision Medicine, Real-world

NSCLC; biomarker testing; overall survival; PD-L1; EGFR; ALK; next-generation sequencing; liquid biopsy; precision medicine; real-world data

BioNTech and BMS Announce First Global Data for PD-L1xVEGF Bispecific in Small Cell Lung Cancer, Set Phase 3 Dose

2 months ago talkbio0Tagged BioNTech, BNT327, Burning Mouth Syndrome, Myers, Overall response rate, PD-L1, PD-L1xVEGF, Pharmacotherapy, pumitamig, Small cell carcinoma of lung, squibb, Vascular Endothelial Growth Factor A

BioNTech; Bristol Myers Squibb; BMS; PD-L1xVEGF bispecific; BNT327; pumitamig; small cell lung cancer; SCLC; phase 2 trial; phase 3 dose; overall response rate; VEGF-A; PD-L1; chemotherapy

Bristol Myers Squibb Commits Up to $11B+ in Major BioNTech Solid Tumor Bispecific Antibody Deal

5 months ago talkbio0Tagged Antibodies, Bispecific, BioNTech, BNT327, Immunotherapy for cancer, milestone payments, Myers, Partnership, PD-L1, Solid Neoplasm, squibb, Vascular Endothelial Growth Factor A

Bristol Myers Squibb; BioNTech; BNT327; bispecific antibody; solid tumors; PD-L1; VEGF-A; cancer immunotherapy; partnership; milestone payments

Bristol Myers Squibb Signs $11B Deal With BioNTech for Bispecific Cancer Antibody BNT327, Surpassing Recent Merck and Pfizer Moves

5 months ago talkbio0Tagged Antibodies, Bispecific, BioNTech, biotech partnerships, BNT327, immuno-oncology, Malignant Neoplasms, Myers, PD-L1, Solid Neoplasm, squibb, Vascular Endothelial Growth Factor A

Bristol Myers Squibb; BioNTech; BNT327; bispecific antibody; immuno-oncology; cancer; PD-L1; VEGF-A; solid tumors; biotech partnerships

Bicara’s Ficerafusp Alfa Shows 46% 2-Year Survival Rate for Head and Neck Cancer Subset at ASCO 2025

5 months ago talkbio0Tagged 2025, Alfa, Antibody Therapy, ASCO, Bicara Therapeutics, Cancer of Neck, Head, Keytruda, Overall Survival, PD-L1, tumor shrinkage

ASCO 2025; Bicara Therapeutics; ficerafusp alfa; head and neck cancer; PD-L1; overall survival; antibody therapy; Keytruda; tumor shrinkage

BioNTech Acquires Biotheus for $800M to Enhance Oncology Strategy with Promising Bispecific Antibody

12 months ago talkbio0Tagged Acquisition, Antibodies, Bispecific, BioNTech, Biotheus, BNT327/PM8002, Cancer Therapeutic Procedure, Neoplasms, PD-L1, Vascular Endothelial Growth Factor A

BioNTech, Biotheus, oncology, bispecific antibody, BNT327/PM8002, PD-L1, VEGF-A, cancer treatment, acquisition

FDA Panel Recommends Limiting Immunotherapy Access for Stomach and Esophageal Cancer Patients Based on PD-L1 Expression

1 year ago talkbio0Tagged Esophageal Neoplasms, Gene Expression, Immunotherapy, Keytruda, Malignant neoplasm of stomach, PD-L1, Tevimbra, United States Food and Drug Administration

FDA, Immunotherapy, Stomach Cancer, Esophageal Cancer, PD-L1 Expression, Keytruda, Opdivo, Tevimbra

FDA Considers Restricting PD-1 Drugs in Stomach and Esophageal Cancers Based on PD-L1 Expression

1 year ago talkbio0Tagged Esophageal Neoplasms, Gene Expression, nivolumab, PD-L1, PDCD1 gene, pembrolizumab, restrictions, tislelizumab, United States Food and Drug Administration

PD-1 drugs, stomach cancer, esophageal cancer, PD-L1 expression, FDA restrictions, pembrolizumab, nivolumab, tislelizumab